NFKB1 and cancer: Bioassays demonstrated potent dose-dependent anti-inflammatory activity through NF-κB suppression, alongside selective cytotoxicity against HepG2 hepatocellular carcinoma cells, indicating therapeutic potential in inflammation-associated cancers.